Zobrazeno 1 - 10
of 773
pro vyhledávání: '"SJ Nam"'
Autor:
SH Cho, Ha Kim, YS Jung, MH Hur, WC Noh, Hyeoung-Joon Kim, SS Kang, SH Han, SH Ahn, Sy Kim, Sa Im, BW Park, ES Lee, KH Park, MH Lee, W Han, SJ Nam, S-H Lee, J Jung, JH Yoon
Publikováno v:
Cancer Research. 79:P4-14
BACKGROUND Assessment of restoration of ovarian function after chemotherapy is critical with respect to the initiation of different types of endocrine treatment in young high risk breast cancer patients METHODS In total, 1289 women who remained preme
Autor:
Ey Cho, SW Kim, S Lee, Je Lee, Y-H Im, Young-Ae Park, Jong Han Yu, Hae Hyun Jung, JS Ahn, Je Lim, SJ Nam, J-Y Kim
Publikováno v:
Cancer Research. 79:P4-08
Introduction: To date, the role of immunotherapy with check point inhibitors and/or vaccines in the treatment of breast cancer (BC) is still debating, and the main focus of immunotherapy in BC is on triple negative subtype as a target population in m
Autor:
Young-Ae Park, SH Hyun, K. Park, Je Lee, Y-H Im, SJ Nam, JS Ahn, Suyeon Park, Eui Jin Lee, SW Kim, HK Ahn, J-Y Kim, S Lee, Jong Han Yu
Publikováno v:
Cancer Research. 79:P3-08
Introduction: PIK3CA mutation is one of the most frequent genomic alterations in breast cancer. We evaluated PIK3CA mutational status including spatial and temporal heterogeneity, clinical characteristics and prognostic impact focused on ER+/HER2- su
Autor:
KH Park, Young-Ae Park, J-Y Kim, S Lee, JS Ahn, Jong Han Yu, W. Park, Y-H Im, Je Lee, SW Kim, SJ Nam
Publikováno v:
Cancer Research. 79:P1-09
Introduction: Genetic alteration of Estrogen Receptor 1(ESR1) gene have been associated with acquired endocrine resistance and occurred in about 20% of endocrine resistant estrogen receptor(ER)-positive metastatic breast cancer(MBC). Mutations in lig
Publikováno v:
Cancer Research. 79:P1-15
This abstract was not presented at the conference. Citation Format: Choi HJ, Kim SW, Ryu JM, Kim I, Nam SJ, Yu J, Lee SK, Lee JE. Not presented [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX
Autor:
Samir Lal, SJ Nam, Y.S. Choi, SW Kim, W. Park, S Lee, S-H Lee, Zhengyan Kan, Yixiao Ding, Shibing Deng, Sripad Ram, Paul A. Rejto, Eric L. Powell, Jong Han Yu, Sy Cho, Vinicius Bonato, Keith A. Ching, Je Lee, Y-H Park, Jadwiga Bienkowska, J-Y Kim
Publikováno v:
Cancer Research. 79:PD5-08
Understanding how standard-of-care drug treatments affect tumor intrinsic biology and microenvironment is critical for elucidating drug resistance mechanisms and developing better combination therapies as well as new therapies. To characterize the ef
Publikováno v:
Cancer Research. 78:P1-07
Purpose Numerous studies demonstrated that breast cancer in young women (BCY) has unfavorable prognostic features and unfavorable subtype. However, there were few studies to evaluate the effect on the prognosis of breast cancer according to the subty
Autor:
JS Ahn, SJ Nam, Young-Ae Park, Sy Cho, Je Lee, Je Lim, J-Y Kim, Jong Han Yu, S Lee, Hae Hyun Jung, Y-H Im, Ey Cho, SW Kim
Publikováno v:
Cancer Research. 78:P1-07
Introduction : Our understanding of biology of breast cancer has led to significant changes in diagnostic and therapeutic approaches for breast cancer, The new eighth edition of the TNM classification of the AJCC for breast cancer (BC) determined by
Autor:
JS Ahn, S Lee, SW Kim, Jong Han Yu, Hae Hyun Jung, J-Y Kim, Young-Ae Park, Y-H Im, W. Park, SJ Nam, K. Park, Je Lee
Publikováno v:
Cancer Research. 78:P6-09
Introduction: Estrogen Receptor 1 (ESR1) gene encodes an estrogen receptor, which regulates cell proliferation and promotes tumor progression in estrogen receptor(ER)-positive breast cancer (BC). Therefore, endocrine therapy that inhibiting ER downst
Autor:
Song Ee Park, H-J Paik, S Lee, Sy Bae, Je Lee, SW Kim, SJ Nam, Isaac Kim, Jonghan Yu, Jai Min Ryu
Publikováno v:
Cancer Research. 77:P5-13
Background: Conditional disease-free survival (CDFS) reflects changes over time. Because traditional disease-free survival (DFS) is estimated from the date of diagnosis, it is limited in the ability to predict risk of recurrence in patients who have